Efficacy of Pregabalin for the Treatment of Acute Herpetic Neuralgia

• Status: Completed
• Trial end date: 2019-12-30
• Target enrollment: 0
• Participant gender: All

Summary

All eligible Herpes Zoster patients will be randomized into two groups. Group 1 will be the treatment group receiving Pregabalin 75 mg twice daily for 4 weeks in addition to other routine treatment. Whereas, group 2 will be the control group receiving all routine treatment similar to group 1 except Pregabalin. Instead control group will receive Placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: B.P. Koirala Institute of Health Sciences
• Collaborators: University Grants Commission; University grants commission, Nepal (Funding source)
• Treatments: Pregabalin

Criteria

Inclusion Criteria:

• Patients of HZ presenting within 72 hours of onset of rash,

• With pain score 40 or above on 100 mm pain Visual Analogue Scale at the screening visit,

• Giving written consent for the study.

• Age between 18-70 years

Exclusion Criteria:

• HZ presenting after 72 hours of onset

• Pain score less than 40 at baseline

• Who took the stable doses of oral analgesics like: NSAIDs, acetaminophen, opioids and antidepressant within six hours of screening visit

• Using Pregabalin and Gabapentin within last 72 hours

• Nerve block therapy within the last 48 hours

• History of hypersensitivity to the drug or its ingredients

• Use of topical medications within 12 hours

• Unable to come for follow up because of severe systemic illness

• Significant hepatic and renal disease,

• Bed ridden patients or those who are physically unfit for follow up visits.

• Ethically considered vulnerable members- pregnant/lactating mothers/newborn/children below 12 years /physically or mentally challenged individuals/HIV/ AIDS/IV drug users